Passkey Therapeutics, a Cambridge, MA-based developer of synergistic multifunctional therapeutics (SMThs), raised $20M in Seed funding.
The round was led by Breakout Ventures along with Innovation Endeavors and Bison Ventures. Additional participants included Wireframe Ventures, Alexandria Venture Investments, and GRIDS Capital.
The company intends to use the funds to support its development of SMThs (pronounced “smiths”), a new class of single-drug therapies designed to modulate rare combinations of proteins that work together, and Locksmith, its proprietary computational and experimental platform for SMTh discovery.
Led by CEO Bruce Beutel, Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs), designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.
The company is progressing its internal pipeline with plans to internally develop SMThs in two distinct therapeutic areas through clinical trials, while also exploring potential partnerships in additional areas.
FinSMEs
22/10/2024